Your profile :General public|Researcher|Student|Companies / Communities|Press
Programme CAPTOR
Investissements d'avenir
The program CAPTORPresentation


Medication is still nowadays the main treatment to fight cancer.

The program CAPTOR (Cancer Pharmacology of Toulouse-Oncopole and Region) is a large research project devoted to innovating, evaluating, and placing on the market anti-cancer medication but also to all training courses linked to these domains. 

Coordinated by Professor Guy Laurent – a Toulouse University Hospital hematologist – and supported by the University Toulouse III - Paul Sabatier, CAPTOR is a winner project of the Investments for the Future (Investissements d’Avenir) launched in 2010 and obtained a 10 million euro budget over 5 years from the French National Research Agency.

This Pôle d’Excellence (Center of Excellence) is one of the main elements of the scientific and medical project Toulouse Oncopole. It benefits from the diverse skills in cancer research of industrial partners situated on the site of Langlade, a network of start-ups but above all researchers from the University Toulouse III-Paul Sabatier, Toulouse University Hospital, the Institute Claudius Regaud, and Toulouse Center for Cancer Research – united in the Toulouse University Institute for Cancer - as well as the skills 

The program CAPTOR succeeded in anticipating the orientations of the Plan Cancer 2014-2018 which was presented in early December 2013. This confirms that « the transfer of scientific discoveries speeds up and benefits to patients », as the French National Cancer Institute (INCa) notes.

Learn more...

CAPTOR fits into the dynamics of the creation of Toulouse-Oncopole which gathers on a same site (Toulouse-Langlade):

  • A hospital totally dedicated to cancer: The University Institute of cancer in Toulouse (IUCT-O), opened in 2014,
  • A large academic research center: Cancer Research Center of Toulouse (CRCT, UMR INSERM 1037) which involves 12 teams and more than 200 people,
  • Industrial research centers and a large network of companies specialized in biotechnologies.

CAPTOR focuses on anti-cancer medicine and consists of four areas:

  • The Innovation area: research on new drugs managed by Dr. Jean Jacques Fournié, director of the Cancer Research Center of Toulouse. 
  • The clinical research area: research on these new drugs from a clinical research point of view. Headed by Professor Michel ATTAL, international specialist of multiple myeloma and director of the Institute Claudius Regaud, and Professor Jean-Pierre Delord, in charge of clinical research for this very same institute.           
  • The Social Pharmacology area: « Medicine in real life » which aims at evaluating the process of placing anti-cancer medication on the market. Run by Professor Guy Laurent, hematologist at the University Hospital of Toulouse.
  • The Education/training area: managed by Professors Roland Bugat and Elie Serrano, it aims at answering the needs of emerging professions in cancer research and contributing to the circulation of knowledge in this domain.

The financing of the project CAPTOR by the French National Research Agency proves the state trusts Toulouse Cancer Research. It is clearly a bonus for innovation as well for fundamental, clinical and societal research, applied to cancer, and gives credit to public and private research laboratories, the University Hospital of Toulouse and the Institute Claudius Regaud. CAPTOR is one of the structuring projects of the Oncopole.


Latest news
03 Mai 2016
Professor Michel Attal receives the ARC Foundation Léopold Griffuel Awards
Professor Michel Attal receives the ARC Foundation Léopold Griffuel Awards

Professor Michel Attal - co-leader of the "Clinical Research" of CAPTOR and director of the University Institute of Toulouse - Oncopole - receives on Tuesday, May 3rd, 2016 in Paris the ARC Foundation Léopold Griffuel Awards, for his research on the multiple myeloma.

Created in 1970 in accordance with the late Mrs Griffuel’s will, the ARC Foundation Léopold Griffuel Awards are one of the most prestigious prizes dedicated exclusively to cancer research. The prizes are awarded by the Board of Directors of the ARC Foundation for Cancer Research after an independent evaluation by an International Scientific Committee.

Since 2014, it rewards two laureates whose work has respectively led to a major breakthrough in basic research and in translational and clinical research. Worth €150,000 each (€25,000 for the laureate and €125,000 for his research), these awards seek to promote and encourage further scientific projects.

Retour à la liste des actualités

Mobile site CAPTOR - Médicaments anti cancerCAPTOR - Médicaments anti cancer
Université Toulouse 3 - Paul Sabatier Inserm CNRS Institut Claudius Regaud CHU de Toulouse IUC Oncopole ANR